• National Coordinator, Principal Investigator, Deputy Principal
  Investigator and Sub-investigator by more than 50 Phase I, II, III and IV clinical trials (Melanoma, MCC, BCC, SCC, adenoid cystic carcinoma, AKs, as also Psoriasis and autoimmune skin diseases) since 07/2013
•  Languages: Greek (mother tongue), English (C2), German (C1)
• Basic cource for aesthetic dermatology/ cosmetology (Arbeitschaft Ästhetische Dermatologie und Kosmetologie-ADK), 07/2023
• GCP Refresher Course, incl. Updates Course, 10/2022
• Strengthen resources! Team-oriented leadership in the hospital, 02-05/2022
• GCP Refresher Course, incl. Updates Course, 02/2021
• Asklepion Academy 4. Tübinger Laserseminar, Tuebingen, 02/2020
• GCP-Aufbaukurs, 06/2019
• Asklepion Academy 3. Tübinger Laserseminar, Tuebingen, 02/2019
• GCP-Training Refresher, 12/2018
• Basic cource for aesthetic dermatology/ cosmetology (Arbeitschaft Ästhetische Dermatologie und Kosmetologie-ADK),10/2018
• Basic cource for aesthetic dermatology/ cosmetology (Arbeitschaft Ästhetische Dermatologie und Kosmetologie-ADK), 10/2017
• Asklepion Academy 1. Tübinger Laserseminar, Tuebingen, 02/2017
• GCP-Training Refresher, 12/2016
• GCP II-Aufbaukurs (inkl. 2. und 3. AMG-Änderungsgesetzt), 01/2015
• GCP Basistraining AMG & MPG, 06/2013
• ILS-ERC (Immediate Life Support,European Resuscitation Council), 2008
• Windows Office (Msword, Powerpoint, Access), Internet, Linux, Mednext (Oracle), Novell, SAP, Groupwise, Meona, Lauris, Centricity Web, ChilliWeb, Citrix, SPSS, Endnote, RedCap

• Hellenic society of Dermatology and Venereology
• European Academy of Dermatology and Venereology (EADV)
• European Association of Dermato Oncology (EADO)
• Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
• Deutsche Krebsgesellschaft (DKG) IOANNIS THOMAS 1
• Deutsche Gesellschaft für Dermatochirurgie e.V.
• Medical association of Baden-Württemberg, Germany
• Medical association of Athens, Greece

• Teaching in the Postgraduate Program “Malignant Skin Cancers”, “Andreas Syngros Hospital” 2024-present
• Teaching and examination of medical students of the University of Tuebingen, Germany (U-Kurs, Nahtkurs, OSCE, PJ-Studenten/ Wochenpraktikanten) since 07/2013

• Dermatology Goes Pop(ular), 22-25 Ιουνίου 2023, Ηράκλειο, Κρήτη
• Course for the adult education center in Stuttgart: The skin, our largest sensory organ, 01/2023, Stuttgart
• Dermatoscopy course 2022, Tuebingen
• Regional government office of Tuebingen 2022, Tuebingen
• Nordschwarzwaldsymposium 2022, Karlsruhe
• Dermatoscopy course 2020, Tuebingen
• Dermatoscopy course 2019, Tuebingen
• Dermatoscopy course 2018, Tuebingen
• Symposium of Immuno-Oncology 2017, Stuttgart
• Dermatoscopy course 2017, Tuebingen
• Symposium of Immuno-Oncology 2016, Stuttgart
• Dermatoscopy course 2016, Tuebingen
• Dermatoscopy course 2015, Tuebingen

MK3475-587 (advanced tumors/ Principal Investigator and National
Coordinator), TED15297 (advanced solid tumors/ Principal Investigator),
ACT16845 (skin tumors/ Principal Investigator), Biontech BNT111-01
(Melanoma/ Principal Investigator), AstraZeneca Monette ATR (Melanoma/
Principal Investigator), BMS-CA224-098 (Melanoma/ Principal Investigator),
BMS-CA224-047 (Melanoma/ Principal Investigator), BMS-CA-027-002
(Melanoma/ Principal Investigator), BMS-CA209-76K (Melanoma/ Principal
Investigator), BMS-CA209-067 (Melanoma/ Principal Investigator), BMSCA209-066 (Melanoma/ Principal Investigator), BMS-CA209-76K (Melanoma/
IOANNIS THOMAS 1
Principal Investigator), BMS-CA209-915 (Melanoma/ Principal Investigator),
BMS-CA209-8TT (Melanoma/ Principal Investigator), BMS-CA045-001
(Melanoma/ Principal Investigator), BMS-CA209-511 (Melanoma/ PrincipalInvestigator), MK3475-252 (Melanoma/ sub-investigator), MK3475-PN002
(Melanoma/ sub-investigator), MK3475-V937-01 (Melanoma/ Principal
Investigator), HUYA-HBI-8000-303 (Melanoma/ Principal Investigator),
BIOTECH-IO102-IO103-013 (Melanoma/ sub-investigator), Novartis
CLXH254C12201 (Melanoma/ Principal Investigator), PIVOT12-NEKTAR
(Melanoma/ Principal Investigator), Philogen Pivotal intratumoral (Melanoma/
sub-investigator), Genentech-BELVA (Melanoma/ Principal Investigator),
Genentech-GO40558 (Melanoma/ Principal Investigator), RadioCoBrim
(Melanoma/ Principal Investigator), AMGEN 20120139 (Melanoma/ Principal
Investigator), NIVOMELA (Melanoma/ Deputy Principal Investigator),
MK3475-716 (Melanoma/ Deputy Principal-Investigator), SNEPS (Melanoma/
Principal Investigator), Roche Imbrella B (tumors/ Principal Investigator),
Roche Trilogy CO39262 (Melanoma/ Deputy Principal Investigator), MK3475-
054 (Melanoma/ Principal Investigator), BMS-CA-209-172 (Melanoma/ subinvestigator), Curevac-CV8102-008 (Melanoma and other tumors/ Principal
Investigator and National Coordinator), CombiAD (Melanoma/ Principal
Investigator), Combi-I (Melanoma/ Principal Investigator), IDERA Illuminate
(Melanoma/ Principal Investigator), 4SC-Sensitize (Melanoma/ Principal
Investigator), IOVANCE C-144-01 (Melanoma/ Principal Investigator),
ImmunoCobiVem2015 (Melanoma/ Principal Investigator), BRAIN-IP
(Melanoma/ sub-investigator), BUMPER (Melanoma/ sub-investigator),
AMGEN20180115 (Melanoma/ Deputy Principal Investigator), Columbus
(Melanoma/ Principal Investigator), 162A2301NEMO (Melanoma/ subinvestigator), IMMUNED (Melanoma/ sub-investigator), AMGEN Masterkey
265 (Melanoma/ sub-investigator), AMGEN Masterkey 264 (Melanoma/ subinvestigator), ADMEC-O (cSCC/ sub-investigator), PHILOGEN L19IL2 i.v.
(Melanoma/ sub-investigator), PACMEL (Melanoma/ sub-investigator),
ORIGIMM-ORI-A-Ce001 (Acne vulgaris/ Deputy Principal Investigator),
DupiMorph (Morphea/ sub-investigator), AMGEN-CC-10004-PSOR-020-
EMBRACE (Psoriasis/ Deputy Principal Investigator), PINPOINTCAIN457ADE15 (Psoriasis/ Deputy Principal Investigator), Leo-LP0160-1396-
EMBRACE-1 (Psoriasis/ Deputy Principal Investigator), ARGNX-113-1904-
ADDRESS (Pemphigus/ Deputy Principal Investigator), ARGNX-113-1905-
ADDRESS + (Pemphigus/ Deputy Principal Investigator), Pelle-926-301
(BCC/ sub-investigator), R2810-ONC-1620 (BCC/ sub-investigator), Philogen
Duncan (BCC, cSCC/ sub-investigator), KRT-232-103 (MCC/ Principal
Investigator), MERKLIN-1 (MCC/ Principal Investigator), MERKLIN-2 (MCC/
Principal Investigator), INCMGA0012-201 (MCC/ sub-investigator), CerpassRPL-002-18 (cSCC/ Deputy Principal Investigator), IFX-1-P2.8 (cSCC/
Principal Investigator), Field Cancerization (cSCC/ sub-investigator), R2810-
ONC-1788 (cSCC/ sub-investigator), MK3475-630 (cSCC/ sub-investigator),
IOANNIS THOMAS 1
MK3475-629 (cSCC/ sub-investigator), Reg2810-ONC-1901 (cSCC/ Principal
Investigator), ALICE (cSCC/ sub-investigator), Reg2810-ONC-1540 (cSCC/
sub-investigator), FLIMMA (Melanoma/ sub-investigator), NEO-VC-UKTRoche IIT (Melanoma/ sub-investigator), Phototox-GSK-Novartis IIT
(Melanoma/ sub-investigator), LEO PICATO (actinic keratosis/ subinvestigator), EMR200066-007 (Melanoma/ sub-investigator), BOTTOM
(Melanoma/ sub-investigator), BRF117277-Combi MB (Melanoma/ subinvestigator), CombiD_MEK115306 (Melanoma/ sub-investigator),
CombiV_MEK116513 (Melanoma/ sub-investigator), DERMA-11482
(Melanoma/ sub-investigator), IMMOMEC (MCC/ sub-investigator), BRIM P
(Melanoma/ sub-investigator), BRIM 8 (Melanoma/ sub-investigator),
NO25026-E-BRIM3 (Melanoma/ sub-investigator), CoBRIM (Melanoma/ subinvestigator), Vemura-EAP MO25515 (Melanoma/ sub-investigator), VEM.
BRAIN MO25743 (Melanoma/ sub-investigator), MIKIE (BCC/ subinvestigator), STEVIE (BCC/ sub-investigator), IMspire170 CO39722
(Melanoma/ sub-investigator), NIS-NICO (Melanoma/ sub-investigator), Niels
(BCC/ sub-investigator), Combi-r (Melanoma/ sub-investigator)

• Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part III: Transcranial Application, Immune Profile, Blood-Brain Barrier, Neuroprotection, Neuromodulation and Neurostimulation.
  

  Cell Physiol Biochem. 2026 Apr 10;60(2):175-188. doi: 10.33594/000000859
  Theuer AE, Exner S, Thomas I, Lang F, Mullins JD, Warlick J, Strassmann G, Eigentler TK, Walter GF

• Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part I: Animal Experiments, Clinical Application and Immunological Abscopal Effect.
  

  Cell Physiol Biochem. 2025 Nov 12;59(6):800-810. doi: 10.33594/000000828
  Theuer AE, Thomas I, Lang F, Borkmann M, Mullins JD, Eigentler TK, Walter GF

• Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098
  

  Journal of Clinical Oncology Vol 43, Number 17_suppl doi.org/10.1200/JCO.2025.43.17_suppl.LBA9500
  Georgina V. Long, Paolo Antonio Ascierto, Jun Guo, Sunandana Chandra, Ahmad A. Tarhini, Eva
  Muñoz Couselo, Michele Del Vecchio, Andreia Cristina De Melo, Helen Gogas, Reinhard Dummer,
  Margaret K. Callahan, Dirk Schadendorf, Peter Koelblinger, Gaelle Quereux, Ioannis Thomas, Bohang
  Chen, Alicia Mun Yen Cheong, Patrick Djidel, Sonia Dolfi, and Hussein A. Tawbi

• Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
  
  

  Journal for ImmunoTherapy of Cancer 2025;13:e009352. doi:10.1136/jitc-2024-009352
  Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, Michael Erdmann, Lucie Heinzerling, Sebastian
  Ochsenreither, Jürgen Krauss, Arjun Oberoi, Caroline Robert, Celeste Lebbe, Juan Martin-Liberal,
  Lukas Koch, Erika Richtig, Patrick Terheyden, Carsten Weishaupt, Peter Mohr, Yulia Semiletova,
  Casilda Llacer Perez, Peter Brossart, Franz Georg Bauernfeind, Michael Fluck, Artem Poltoratskiy,
  Marina Sekacheva, Ainara Soria, Beate Schmitt-Bormann, Marina Gonzalez, Jana Heß, Peter
  Wengenmayer, Tobias Seibel, Sven D Koch, Gianluca Quintini, Paula Codó, Martin Falk,
  Oliver Schönborn-Kellenberger, Ulrike Gnad-Vogt26

• EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy
  

  J Am Acad Dermatol . 2023 Nov;89(5):1072-1074. doi: 10.1016/j.jaad.2023.06.057. Epub 2023 Jul 22
  Teresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, Tobias Sinnberg, Heike Niessner, Jing Zhao,
  Sandra Stephanie Ring, Markus Joerger, Christopher Schroeder, Sorin Armeanu-Ebinger, Antonio
  Cozzio, Ulrike Leiter, Ioannis Thomas, Wolfram Jochum, Claus Garbe, Stephan Forchhammer, Mitchell
  Levesque, Joanna Mangana, Michael Hölzel, Reinhard Dummer, Christian M Schürch, Andrea
  Forschner, Lukas Flatz

• Adjuvant immunotherapy with nivolumab versus observation in completely
  resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from
  a randomised, open-label, phase 2 trial
  

  The Lancet DOI: https://doi.org/10.1016/S0140-6736(23)00769-9
  Jürgen C Becker, Selma Ugurel, Ulrike Leiter, Friedegund Meier, Ralf Gutzmer, Sebastian Haferkamp,
  Lisa Zimmer, Elisabeth Livingstone, Thomas K Eigentler, Axel Hauschild, Felix Kiecker, Jessica C
  Hassel, Peter Mohr, Michael Fluck, Ioannis Thomas, Marlene Garzarolli,
  Imke Grimmelmann, Konstantin Drexler, Alexandra N Spillner, Sebastian Eckhardt, Dirk Schadendorf, on
  behalf of DeCOG

• Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving
  
  

  Complete Response Under Anti-PD-1-Based Immunotherapy

  Am J Clin Dermatol . 2023 May;24(3):453-467. doi: 10.1007/s40257-023-00775-7
  Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas Meiwes,
  Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike Niessner, Tobias
  Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral

• Long-term outcomes in melanoma patients achieving a complete response
  under immune checkpoint inhibition
  

  IOTECH Immuno-oncology and technology DOI:https://doi.org/10.1016/j.iotech.2022.100194
  E. Chatziioannou, U. Leiter-Stoppke, I. Thomas, U. Keim, A. Forschner, L. Flatz, T.M.S. Amaral

• 786 Intratumorally administered CV8102 in patients with advanced solid
  tumors: preliminary results from ongoing expansion part in study 008
  

  Journal for ImmunoTherapy of Cancer 10 (Suppl 2):A817-A817 DOI: 10.1136/jitc-2022-SITC2022.0786
  Conference Paper: SITC 37th Annual Meeting (SITC 2022)
  Thomas Eigentler, Igor Samoylenko, Sebastian Ochsenreither, Erika Richtig, Ioannis Thomas, Michael
  Erdmann, Celeste Lebbe, Juan José Soto-Castillo, Patrick Terheyden, Artem Poltoratskiy, Marina
  Sekacheva, Yuliya Semiletova, Janina Henze, Beate Schmitt-Bormann, Paula Codó, Martin Falk, Ulrike
  Gnad-Vogt

• 784 Immune profiling of patients with advanced melanoma intratumorally
  treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion
  

  Journal for ImmunoTherapy of Cancer 10(Suppl 2):A815-A815 DOI: 10.1136/jitc-2022-SITC2022.0784
  Conference: SITC 37th Annual Meeting (SITC 2022)
  Marina Gonzalez, Peter Wengenmayer, Igor Samoylenko, Sebastian Ochsenreither, Erika Richtig,
  Ioannis Thomas, Michael Erdmann, Celeste Lebbe, Juan Martin-Liberal, Patrick Terheyden, Artem
  Poltoratskiy, Marina Sekacheva, Yuliya Semiletova, Thomas Eigentler, Beate Schmitt-Bormann, Dominik
  Vahrenhorst, Sarah-Katharina Kays, Tobias Seibel, Gianluca Quintini, Birgit Scheel, Martin Falk, Ulrike
  Gnad-Vogt, Paula Codó

• Association between Immune-Related Adverse Events and Survival in 319
  Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
  Cancers 2021, 13(23), 6141; https://doi.org/10.3390/cancers13236141
  

  Lina María Serna Higuita, Teresa Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, Olivia Seeber,
  Ioannis Thomas, Claus Garbe, Thomas Kurt Eigentler, Peter Martus

• Sequential targeted and immunotherapies in stage IV melanoma
  

  Annals of Oncology, DOI:https://doi.org/10.1016/j.annonc.2021.08.1429
  T.M.S. Amaral, J. Nolinski, H. Niessner, T. Sinnberg, O. Seeber, S. Sanchez, U. Keim, I. Thomas, A.
  Meiwes, A. Koechel, A. Forschner, U. Leiter, L. Flatz, T. Eigentler, C. Garbe

• Primary resistance to checkpoint inhibition
  Cancers, DOI: 10.3390/cancers12041027
  

  Teresa Amaral, Olivia Seeber, Ioannis Thomas, Andreas Meiwes, Andrea Forschner, Ulrike Leiter,
  Thomas Eigentler, Ulrike Keim, Claus Garbe

• Primary resistance to immune-checkpoint inhibitors in patients with metastatic
  melanoma
  

  Journal of Translational Medicine 2020, 18(Supp 1):16
  Teresa Amaral, Zeinab Assi, Ulrike Keim, Andreas Meiwes, Ioannis Thomas, Julia Wilhelmi, Thomas
  Eigentler, Claus Garbe, Olivia Seeber

• An open-label, single-arm, phase II trial of buparlisib in patients with
  melanoma brain metastases not eligible for surgery or radiosurgery-the
  BUMPER study NeuroOncology Advances, https://doi.org/10.1093/noajnl/vdaa140
  

  Teresa Amaral, Heike Niessner, Tobias Sinnberg, Ioannis Thomas, Andreas Meiwes, Claus Garbe,
  Marlene Garzarolli, Ricarda Rauschenberg, Thomas Eigentler, Friedegund Meier

• Late recurrence of melanoma after 10 years – Is the course of the disease
  different from early recurrences?
  

  Journal of the European Academy of Dermatology and Venereology DOI: 10.1111/jdv.16106E
  E Sarac, J Wilhelmi, I Thomas, U Leiter, U. Keim, T Eigentler, C Garbe, T Amaral

• Immune-related adverse events associated with checkpoint inhibitors therapy
  in a real world setting
  

  Journal: Journal of Translational Medicine, 2019, 17(Supp 1): 14
  Teresa Amaral, Thomas Eigentler, Paloma Caballero, Ioanna Tampouri, Diana Lomberg, Zeinab Assi,
  Ioannis Thomas, Ansgar Koechel, Alisa Mueller, Lukas Kofler, Ulrike Leiter, Andrea Forschner, Claus
  Garbe

• Cutaneous, gastrointestinal, hepatic, endocrine and renal side effects of antiPD-1 therapy
  European Journal Of Cancer 2016, DOI: 10.1016/j.ejca.2016.02.025
  

  Hofmann L, Forschner A, Loquai C, Goldinger S, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal
  JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U,
  Garbe C, Kirchberger M, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G,
  Dummer R, Heinzerling L

• Neurological, respiratory, musculoskeletal, cardiac and ocular side effects of
  anti-PD-1 therapy
  

  European Journal Of Cancer 2016, DOI: 10.1016/j.ejca.2016.02.024
  Zimmer L, Goldinger S, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen M, Gutzmer R, Utikal J,
  Göppner D, Hassel J, Meier F, Tietze J, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U,
  Garbe C, Kirchberger M, Eigentler T, Berking C, Gesierich A, Krackhardt A, Schadendorf D, Schuler G,
  Dummer R, Heinzerling L

• Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte
  (TIL) cell therapy: A post hoc analysis of the C-144-01 trial of lifileucel in
  patients with advanced melanoma
  

  Annals of Oncology (2022) 16 (suppl_1): 100101-100101. 10.1016/iotech/iotech100101
  ESMO IO 2022
  Jessica C. Hassel, Amod Sarnaik, Jason Chesney, Theresa Medina, Omid Hamid, Sajeve Thomas,
  Martin Wermke, Evidio Domingo-Musibay, John M. Kirkwood, James Larkin, Jeffrey Weber, Ana Maria
  Arance Fernandez, Juan Francisco Rodríguez Moreno, Ioannis Thomas, Alfonso Berrocal Jaime, Pippa
  Corrie, Viktoria Gontcharova, Xiao Wu, Wen Shi, Harriet Kluger

• Adjuvant immunotherapy with nivolumab vs. observation in completely
  resected Merkel cell carcinoma (MCC): Disease-free survival results from
  ADMEC-O, a randomized, open-label phase 2 trial
  

  September 2022 Annals of Oncology 33:S903 DOI: 10.1016/j.annonc.2022.07.913 ESMO 2022
  J.C. Becker, S. Ugurel, U. Leiter, F. Meier, R. Gutzmer, S. Haferkamp, L. Zimmer, E. Livingstone, T.
  Eigentler, A. Hauschild, F. Kieker, J.C. Hassel, Pe. Mohr, M. Fluck, I. Thomas, M. Garzarolli, I.
  Grimmelmann, K. Drexler, S.Eckhardt, D. Schadendorf on behalf of the DeCOG

• Unerwünschte kardiale Nebenwirkungen unter BRAF- und MEK-InhibitorTherapie
  

  32. Deutscher Hautkrebskongress 2022 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
  I. Bössenecker, O. Seeber, A. Meiwes, S. Sanchez Gonzalez, H. Niessner, T. Sinnberg,
  I. Thomas, A. Forschner, U. Leiter-Stöppke, C. Garbe, L. Flatz, T. Eigentler, T. Amaral

• Which method should be used to evaluate body composition as a predictive
  factor for immunotherapy response in melanoma patients? A one center
  survey
  
  

  32. Deutscher Hautkrebskongress 2022 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
  S. Sanchez Gonzalez, L. Serna-Higuita, S. Afat, I. Thomas, O. Seeber, I. Bössenecker, U. LeiterStöppke, C. Garbe, L. Flatz, T. Eigentler, T. Amaral

• Sarkoidose unter Immun-Checkpoint-Inhibitoren
  

  28. Deutscher Hautkrebskongress 2018 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
  Tampouri I., Lomberg D., Assi Z., Thomas I., Koechel A., Amaral T., Silber T., Müller A., Kofler L.,
  Forschner A., Garbe C., Eigentler T.

• Myasthenia gravis unter Systemtherapie mit der kombinierten Immuntherapie
  Ipilimumab und Nivolumab
  

  28. Deutscher Hautkrebskongress 2018 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
  Toni Silber, Irina Gepfner-Tuma, Alisa Müller, Ioannis Thomas, Katrin Schweinzer, Lukas Kofler, Diana
  Lomberg, Ansgar Koechel, Ioanna Tampouri, Thomas Eigentler, Claus Garbe, Ghazaleh Tabatabai,
  Andrea Forschner

• Zunehmender Schwindel, Übelkeit und Ataxie unter einer kombinierten
  Immuntherapie bei Malignem Melanom St. IV
  

  28. Deutscher Hautkrebskongress 2018 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
  Alisa Müller, Irina Gepfner- Tuma, Teresa Amaral, Gazaleh Tabatabai, Lukas Kofler, Toni Silber, Katrin
  Schweinzer, Ioannis Thomas, Gwendolyn Glatthaar, Diana Lomberg, Ioanna Tampouri, Thomas
  Eigentler, Claus Garbe, Andrea Forschner

• Galvanotherapy effectively necrotizes cutaneous melanoma metastases and
  has the potential as a tumor antigen releasing therapy
  

  13th congress of the EADO 2017
  Ioanna Tampouri, Maximilian Gassenmaier, Heike Niessner, Tobias Sinnberg, Ioannis Thomas, Claus
  Garbe

• Drug reaction with eosinophilia and systemic symptoms (DRESS) nach
  Einnahme von Vemurafenib und Cobimetinib bei metastasiertem Melanom
  

  27. Deutscher Kongress ADO 2017 Tampouri I., Thomas I, Koechel A, Meiwes A, Wilhelmi J, Lomberg D, Pierchalla K, Garbe C, Eigentler T.

• Basal cell carcinoma: two cases of vismodegib therapy in extended advanced
  BCC
  

  13th EADV Spring symposium 2016
  Tampouri I, Eigentler T, Weide B, Thomas I, Lomberg D, Spänkuch I, Garbe C, Leiter U